Cited by 336Renal cell carcinoma treatmentCancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.

The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma

Open access

Kaelin, William G.·2007·Clinical Cancer Research

Open this paper in CoChat — free account Open PDF

Abstract

Germ line VHL tumor suppressor gene loss-of-function mutations cause von Hippel-Lindau disease, which is associated with an increased risk of central nervous system hemangioblastomas, clear cell renal carcinomas, and pheochromocytomas. Somatic VHL mutations are also common in sporadic clear cell renal carcinomas. The VHL gene product, pVHL, is part of a ubiquitin ligase complex that targets the α-subunits of the heterodimeric transcription factor hypoxia-inducible factor (HIF) for polyubiquitylation, and hence, proteasomal degradation, when oxygen is available. pVHL-defective clear cell renal carcinomas overproduce a variety of mRNAs that are under the control of HIF, including the mRNAs that encode vascular endothelial growth factor, platelet-derived growth factor B, and transforming growth factor α. In preclinical models, down-regulation of HIF-α, especially HIF-2α, is both necessary and sufficient for renal tumor suppression by pVHL. These observations are probably relevant to the demonstrated clinical activity of vascular endothelial growth factor antagonists in clear cell renal carcinoma and form a foundation for the testing of additional agents that inhibit HIF, or HIF-responsive gene products, in this disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-06-1865

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O 2 -Regulated Prolyl Hydroxylation
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Self-citation
Untitled work
(2000) · PubMed · Cited by 1,445
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. K., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,361
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,234

Show all 80 references

Sorted by citations

HIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P. J., Cohen, P. A., Golshayan, A., Rayman, P. A., Wood, L. S., García, J. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 861
Hypoxia and cancer
Brahimi-Horn, M. C., Chiche, J., & Pouysségur, J. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0281-3 · Cited by 765
Targeting the ubiquitin system in cancer therapy
Hoeller, D., & Đikić, I. (2009) · Nature · doi:10.1038/nature07960 · Cited by 605
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling
Adam, J., Hatipoglu, E., O'Flaherty, L., Ternette, N., Sahgal, N., Lockstone, H., Baban, D., Nye, E., Stamp, G. W., Wolhuter, K., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.006 · Cited by 585
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
Motzer, R. J., Banchereau, R., Hamidi, H., Powles, T. B., McDermott, D. F., Atkins, M. B., Escudier, B. J., Liu, L.-F., Leng, N., Abbas, A. R., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.10.011 · Cited by 584
Renal cell carcinoma
Cairns, P. (2011) · Cancer Biomarkers · doi:10.3233/cbm-2011-0176 · Cited by 511
Therapeutic targeting of the hypoxic tumour microenvironment
Singleton, D. C., Macann, A., & Wilson, W. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00539-4 · Cited by 507
Phospholipase D: Enzymology, Functionality, and Chemical Modulation
Selvy, P. E., Lavieri, R. R., Lindsley, C. W., & Brown, H. A. (2011) · Chemical Reviews · doi:10.1021/cr200296t · Cited by 406
Renal cell carcinoma
Rini, B. I., Campbell, S. C., & Rathmell, W. K. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000219260.60714.c4 · Cited by 380
VHL and HIF signalling in renal cell carcinogenesis
Baldewijns, M. M. L. L., van Vlodrop, I. J. H., Vermeulen, P. B., Soetekouw, P. M. M. B., van Engeland, M., & de Bruı̈ne, A. P. (2010) · The Journal of Pathology · doi:10.1002/path.2689 · Cited by 326
Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2
Toschi, A., Lee, E., Gadir, N., Ohh, M., & Foster, D. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.c800170200 · Cited by 313
Mitochondria and cellular oxygen sensing in the HIF pathway
Taylor, C. T. (2008) · Biochemical Journal · doi:10.1042/bj20071249 · Cited by 298
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy
Finke, J. H., Ko, J. S., Rini, B. I., Rayman, P. A., Ireland, J. L., & Cohen, P. A. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.030 · Cited by 281
Cell polarity and cancer – cell and tissue polarity as a non-canonical tumor suppressor
Lee, M., & Vasioukhin, V. I. (2008) · Journal of Cell Science · doi:10.1242/jcs.016634 · Cited by 284
Revisiting the TCA cycle: signaling to tumor formation
Raimundo, N., Baysal, B. E., & Shadel, G. S. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.06.001 · Cited by 281
Development of HIF‐1 inhibitors for cancer therapy
Onnis, B., Rapisarda, A., & Melillo, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00876.x · Cited by 268
Revisiting the HIF switch in the tumor and its immune microenvironment.
Cowman, S. J., & Koh, M. Y. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2021.10.004 · Cited by 256
The Lysyl Oxidases LOX and LOXL2 Are Necessary and Sufficient to Repress E-cadherin in Hypoxia
Schietke, R. E., Warnecke, C., Wacker, I., Schödel, J., Mole, D. R., Câmpean, V., Amann, K., Goppelt‐Struebe, M., Behrens, J., Eckardt, K., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.042424 · Cited by 266
Regulatory mechanisms of hypoxia‐inducible factor 1 activity: Two decades of knowledge
Koyasu, S., Kobayashi, M., Gotö, Y., Hiraoka, M., & Harada, H. (2017) · Cancer Science · doi:10.1111/cas.13483 · Cited by 233
The Warburg metabolism fuels tumor metastasis
Lu, J. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09794-5 · Cited by 221
Hypoxia/pseudohypoxia‐mediated activation of hypoxia‐inducible factor‐1α in cancer
Hayashi, Y., Yokota, A., Harada, H., & Huang, G. (2019) · Cancer Science · doi:10.1111/cas.13990 · Cited by 229
Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets
Tan, S. K., Hougen, H. Y., Merchan, J. R., Gonzalgo, M. L., & Welford, S. M. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00654-6 · Cited by 181
HIF in Kidney Disease and Development
Gunaratnam, L., & Bonventre, J. V. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008070804 · Cited by 178
Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Peña, C. E., Lathia, C. D., Shan, M., Escudier, B. J., & Bukowski, R. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3343 · Cited by 178
Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
Jin, J., Xie, Y., Zhang, J.-S., Wang, J., Dai, S.-J., He, W., Li, S.-Y., Ashby, C. R., Chen, Z., & He, Q. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100929 · Cited by 185
Alterations in VHL as potential biomarkers in renal-cell carcinoma
Gossage, L., & Eisen, T. G. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.42 · Cited by 168
VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy
Cowey, C. L., & Rathmell, W. K. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0015-5 · Cited by 163
Mechanisms of mTOR inhibitor resistance in cancer therapy
Carew, J. S., Kelly, K. R., & Nawrocki, S. T. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0167-8 · Cited by 164
State of the Science: An Update on Renal Cell Carcinoma
Jonasch, E. W., Futreal, P. A., Davis, I. J., Bailey, S. T., Kim, W. Y., Brugarolas, J., Giaccia, A. J., Kurban, G., Pause, A., Frydman, J., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0117 · Cited by 166
Nitric oxide signaling in hypoxia
Ho, J. J. D., Man, H. S. J., & Marsden, P. A. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0880-5 · Cited by 155
Hypoxia‐inducible factor 1 and cancer pathogenesis
Semenza, G. L. (2008) · IUBMB Life · doi:10.1002/iub.93 · Cited by 150
Vascular endocan (ESM‐1) is markedly overexpressed in clear cell renal cell carcinoma
Leroy, X., Aubert, S., Laurent Zini, A., Franquet, H., Kervoaze, G., Villers, A. A., Delehedde, M., Copin, M., & Lassalle, P. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03458.x · Cited by 141
Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress
Hasmim, M., Messai, Y., Ziani, L., Thiery, J., Bouhris, J.-H., Noman, M. Z., & Chouaı̈b, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00482 · Cited by 148
Mechanisms of resistance to anti-angiogenesis therapies
Giuliano, S., & Pagès, G. (2013) · Biochimie · doi:10.1016/j.biochi.2013.03.002 · Cited by 147
Hyperbaric oxygen therapy activates hypoxia‐inducible factor 1 ( HIF ‐1), which contributes to improved wound healing in diabetic mice
Sunkari, V. G., Lind, F., Botusan, I. R., Kashif, A., Liu, Z., Ylä‐Herttuala, S., Brismar, K., Velazquez, O. C., & Catrina, S. (2014) · Wound Repair and Regeneration · doi:10.1111/wrr.12253 · Cited by 137
HOXA9 inhibits HIF-1α-mediated glycolysis through interacting with CRIP2 to repress cutaneous squamous cell carcinoma development
Zhou, L., Wang, Y., Zhou, M., Zhang, Y., Wang, P., Li, X., Yang, J., Wang, H., & Ding, Z. (2018) · Nature Communications · doi:10.1038/s41467-018-03914-5 · Cited by 133
Genetics and epigenetics of renal cell cancer
Baldewijns, M. M. L. L., van Vlodrop, I. J. H., Schouten, L. J., Soetekouw, P. M. M. B., de Bruı̈ne, A. P., & van Engeland, M. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.12.002 · Cited by 133
Polo-like Kinase 3 Functions as a Tumor Suppressor and Is a Negative Regulator of Hypoxia-Inducible Factor-1α under Hypoxic Conditions
Yang, Y., Bai, J., Shen, R. Z., Brown, S. A. N., Komissarova, E. V., Huang, Y., Jiang, N., Alberts, G. F., Costa, M., Luo, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6182 · Cited by 126
Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms
Liang Cheng, C., Zhang, S., MacLennan, G. T., Antonio Lopez-beltran, B., & Montironi, R. (2008) · Human Pathology · doi:10.1016/j.humpath.2008.09.009 · Cited by 124
Malignant Renal Tumors
Campbell, S. C., & Lane, B. R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00049-9 · Cited by 122
ITPR1 Protects Renal Cancer Cells against Natural Killer Cells by Inducing Autophagy
Messai, Y., Noman, M. Z., Hasmim, M., Janji, B., Tittarelli, A., Boutet, M., Baud, V., Viry, E., Billot, K., Nanbakhsh, A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0303 · Cited by 119
Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels
Mahalingam, D., Medina, E. C., Esquivel, J., Espitia, C. M., Smith, S. A., Oberheu, K., Swords, R. T., Kelly, K. R., Mita, M. M., Mita, A. C., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1385 · Cited by 118
Sunitinib in solid tumors
Gan, H. K., Šeruga, B., & Knox, J. J. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902980171 · Cited by 119
Renal Cystic Diseases and Renal Neoplasms
Bonsib, S. M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02020309 · Cited by 118
MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma
Green, N. H., Galvan, D. L., Badal, S. S., Chang, B. H., LeBleu, V. S., Long, J., Jonasch, E., & Danesh, F. R. (2019) · Oncogene · doi:10.1038/s41388-019-0869-4 · Cited by 119
Alu-Alurecombination underlies the vast majority of largeVHLgermline deletions: Molecular characterization and genotype-phenotype correlations in VHL patients
Franke, G., Bausch, B., Hoffmann, M. M., Cybulla, M., Wilhelm, C., Kohlhase, J., Scherer, G., & Neumann, H. P. H. (2009) · Human Mutation · doi:10.1002/humu.20948 · Cited by 114
The sonic hedgehog signaling pathway is reactivated in human renal cell carcinoma and plays orchestral role in tumor growth
Dormoy, V., Danilin, S., Lindner, V., Thomas, L., Rothhut, S., Coquard, C., Helwig, J., Didier Jacqmin, D., Lang, H., & Massfelder, T. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-123 · Cited by 110
MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
Aubert, S., Fauquette, V., Hémon, B., Lepoivre, R., Briez, N., Bernard, D., SEUNINGEN, I. V., Leroy, X., & Perrais, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4905 · Cited by 121
Renal cell carcinoma
Rini, B. I., Rathmell, W. K., & Godley, P. A. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f9782b · Cited by 109
The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis
Myszczyszyn, A., Czarnecka, A. M., Matak, D., Szymański, Ł., Lian, F., Kornakiewicz, A., Bartnik, E., Kukwa, W., Kiéda, C., & Szczylik, C. A. (2015) · Stem Cell Reviews and Reports · doi:10.1007/s12015-015-9611-y · Cited by 109
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma
Ruan, J., Hajjar, K. A., Rafii, S., & Leonard, J. P. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn666 · Cited by 106
Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib
Porta, C., Paglino, C., AMICI, M. D., Quaglini, S., Sacchi, L., Imarisio, I., & Canipari, C. (2010) · Kidney International · doi:10.1038/ki.2009.552 · Cited by 100
Generation of a Mouse Model of Von Hippel–Lindau Kidney Disease Leading to Renal Cancers by Expression of a Constitutively Active Mutant of HIF1α
Fu, L., Wang, G., Shevchuk, M. M., Nanus, D. M., & Gudas, L. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1745 · Cited by 102
Biomarkers in Tumor Angiogenesis and Anti-Angiogenic Therapy
Pircher, A., Hilbe, W., Heidegger, I. M., Drevs, J., Tichelli, A., & Medinger, M. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12107077 · Cited by 92
Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma
Schmidinger, M., & Joaquim Bellmunt, B. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.01.003 · Cited by 92
Recent developments in the treatment of renal cell carcinoma
Dutcher, J. P. (2013) · Therapeutic Advances in Urology · doi:10.1177/1756287213505672 · Cited by 91
Role of VHL gene mutation in human renal cell carcinoma
Arjumand, W., & Sultana, S. (2011) · Tumor Biology · doi:10.1007/s13277-011-0257-3 · Cited by 91
Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression
Klomp, J. A., Petillo, D., Niemi, N. M., Dykema, K. J., Chen, J., Yang, X. J., Sääf, A. M., Zickert, P., Aly, M., Bergerheim, U. S. R., et al. (2010) · BMC Medical Genomics · doi:10.1186/1755-8794-3-59 · Cited by 89
The Role of Hypoxia in Orthodontic Tooth Movement
Niklas, A., Proff, P., Gosau, M., & Römer, P. (2013) · International Journal of Dentistry · doi:10.1155/2013/841840 · Cited by 88
VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKCδ-driven migration
Razorenova, O. V., Finger, E. C., Colavitti, R., Chernikova, S. B., Boiko, A. D., Chan, C. K. F., Krieg, A. J., Bedogni, B., LaGory, E. L., Weissman, I. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011777108 · Cited by 91
Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
Kammerer‐Jacquet, S., Deleuze, A., Saout, J., Mathiéu, R., Laguerre, B., Verhoest, G., Dugay, F., Belaud‐Rotureau, M., Bensalah, K., & Rioux-Leclercq, N. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071692 · Cited by 88
COMP-Ang1 stimulates HIF-1α–mediated SDF-1 overexpression and recovers ischemic injury through BM-derived progenitor cell recruitment
Youn, S., Lee, S.-W., Lee, J., Jeong, H.-K., Suh, J., Yoon, C., Kang, H., Kim, H.-Z., Koh, G.-Y., Oh, B., et al. (2011) · Blood · doi:10.1182/blood-2010-07-295964 · Cited by 86
The role of hypoxia inducible factor-1alpha in gynecological cancer
Seeber, L. M. S., Horrée, N., Vooijs, M., Heintz, A. P. M., van der Wall, E., Verheijen, R. H. M., & van Diest, P. J. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.05.003 · Cited by 85
Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy
Youssoufian, H., Hicklin, D. J., & Rowinsky, E. K. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1107 · Cited by 81
Optimal targeting of the mTORC1 kinase in human cancer
Lane, H. A., & Breuleux, M. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.016 · Cited by 75
Primary clear cell renal carcinoma cells display minimal mitochondrial respiratory capacity resulting in pronounced sensitivity to glycolytic inhibition by 3-Bromopyruvate
Nilsson, H., Lindgren, D., Forsberg, A. M., Mulder, H., Axelson, H., & Johansson, M. (2015) · Cell Death and Disease · doi:10.1038/cddis.2014.545 · Cited by 77
The expression pattern of matrix-producing tumor stroma is of prognostic importance in breast cancer
Winslow, S., Lindquist, K. E., Edsjö, A., & Larsson, C. (2016) · BMC Cancer · doi:10.1186/s12885-016-2864-2 · Cited by 74
Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review)
Song, G., Li, Y., & Jiang, G. (2012) · Oncology Reports · doi:10.3892/or.2012.2045 · Cited by 75
Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review
Kim, B. J., Kim, J. H., Kim, H. S., & Zang, D. Y. (2017) · Oncotarget · doi:10.18632/oncotarget.14704 · Cited by 76
Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma
Ingels, A., Campi, R., Umberto Capitanio, A., Amparore, D., Bertolo, R. G., Carbonara, U., Erdem, S., Kara, Ö., Klatte, T., KRIEGMAIR, M. C., et al. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00592-3 · Cited by 74
Histone Deacetylase Inhibitors: The Epigenetic Therapeutics That Repress Hypoxia‐Inducible Factors
Chen, S., & Sang, N. (2010) · BioMed Research International · doi:10.1155/2011/197946 · Cited by 73
Sunitinib in the treatment of metastatic renal cell carcinoma
Schmid, T. A., & Gore, M. E. (2016) · Therapeutic Advances in Urology · doi:10.1177/1756287216663979 · Cited by 71
Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma
Ballesteros, P. Á., Chamorro, J., Román, M. S., Pozas, J., Santos, V. G. D., Granados, Á. R., Grande, E., Alonso‐Gordoa, T., & Molina‐Cerrillo, J. (2021) · Cancers · doi:10.3390/cancers13235981 · Cited by 74
18 F-FDG PET/CT Imaging for an Early Assessment of Response to Sunitinib in Metastatic Renal Carcinoma: Preliminary Study
Vercellino, L., Bousquet, G., Baillet, G. Y., Barré, E., Mathieu, O., Just, P., Desgrandchamps, F., Misset, J. L., Hindié, E., & Moretti, J. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2008.0527 · Cited by 67
Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence
Rizzo, M., & Porta, C. (2017) · Therapeutic Advances in Urology · doi:10.1177/1756287217713902 · Cited by 66
Surgical resection of endolymphatic sac tumors in von Hippel‐Lindau disease: Findings, results, and indications
Kim, H. J., Hagan, M., Butman, J. A., Baggenstos, M., Brewer, C. C., Zalewski, C. K., Linehan, W. M., & Lonser, R. R. (2012) · The Laryngoscope · doi:10.1002/lary.23646 · Cited by 64
Von Hippel Lindau Syndrome
Kim, J., Rini, B. I., & Hansel, D. E. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6448-9_22 · Cited by 64
Hsp90 as a Gatekeeper of Tumor Angiogenesis: Clinical Promise and Potential Pitfalls
Bohonowych, J. E. S., Gopal, U., & Isaacs, J. S. (2010) · Journal of Oncology · doi:10.1155/2010/412985 · Cited by 64
Vascular Endothelial Growth Factor–Targeted Therapies in Advanced Renal Cell Carcinoma
Albiges, L. K., Salem, M. E., Rini, B. I., & Escudier, B. J. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.04.006 · Cited by 62
Nitric Oxide and Hypoxia Signaling
Man, H. S. J., Tsui, A. K. Y., & Marsden, P. A. (2014) · Vitamins and hormones · doi:10.1016/b978-0-12-800254-4.00007-6 · Cited by 65
A three‐gene expression signature model to predict clinical outcome of clear cell renal carcinoma
Yao, M., Huang, Y. K., Shioi, K., Hattori, K., Murakami, T., Sano, F., Baba, M., Kondo, K., Nakaigawa, N., Kishida, T., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23641 · Cited by 61
HIFα expression in VHL-deficient renal cancer cells is dependent on phospholipase D
Toschi, A., Edelstein, J., Rockwell, P., Ohh, M., & Foster, D. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210927 · Cited by 61
Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma
Santoni, M., Pantano, F., Amantini, C., Nabissi, M., Conti, A., Burattini, L., Zoccoli, A., Berardi, R., Santoni, G., Tonini, G., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.01.007 · Cited by 60
Stabilization of HIF-2α through redox regulation of mTORC2 activation and initiation of mRNA translation
Nayak, B. K., Féliers, D., Sudarshan, S., Friedrichs, W. E., Day, R. T., New, D. D., Fitzgerald, J. P., Eid, A. A., DeNapoli, T. S., Parekh, D. J., et al. (2012) · Oncogene · doi:10.1038/onc.2012.333 · Cited by 60
Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience
Osanto, S., & van der Hulle, T. (2018) · Therapeutic Advances in Urology · doi:10.1177/1756287217748867 · Cited by 59
Expression of the PTTG1 Oncogene Is Associated with Aggressive Clear Cell Renal Cell Carcinoma
Wondergem, B., Zhang, Z., Huang, D., Ong, C. K., Koeman, J. M., Hof, D. V., Petillo, D., Ooi, A., ANEMA, J. G., Lane, B. R., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2330 · Cited by 57
Mutual Regulation of Hypoxia-Inducible Factor and Mammalian Target of Rapamycin as a Function of Oxygen Availability
Knaup, K. X., Jozefowski, K., Schmidt, R., Bernhardt, W. M., Weidemann, A., Jürgensen, J. S., Warnecke, C., Eckardt, K., & Wiesener, M. S. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0288 · Cited by 56
PTEN suppression of YY1 induces HIF-2 activity in von hippel lindau null renal cell carcinoma
Petrella, B. L., & Brinckerhoff, C. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.14.8880 · Cited by 55
Identification and Functional Characterization of pVHL-Dependent Cell Surface Proteins in Renal Cell Carcinoma
Boysen, G., Bausch‐Fluck, D., Thoma, C. R., Nowicka, A. M., Stiehl, D. P., Cima, I., Luu, V.-D., von Teichman, A., Hermanns, T., Sulser, T., et al. (2012) · Neoplasia · doi:10.1596/neo.12130 · Cited by 54
Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy
Mattila, K. E., Vainio, P., & Jaakkola, P. (2022) · Cancers · doi:10.3390/cancers14010239 · Cited by 61
von Hippel-Lindau (VHL) Disease
Shehata, B. M., Stockwell, C. A., Castellano-Sanchez, A. A., Setzer, S. V., Schmotzer, C. L., & Robinson, H. B. (2008) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31816f852e · Cited by 53
Independent association of PD‐L1 expression with noninactivated VHL clear cell renal cell carcinoma—A finding with therapeutic potential
Kammerer‐Jacquet, S., Crouzet, L., Brunot, A., Dagher, J., Pladys, A., Edeline, J., Laguerre, B., Peyronnet, B., Mathiéu, R., Verhoest, G., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30429 · Cited by 52
von Hippel-Lindau Disease
Shanbhogue, K., Hoch, M., Fatterpaker, G., & Chandarana, H. (2016) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2015.12.004 · Cited by 49
NCCN Task Force Report: mTOR Inhibition in Solid Tumors
Figlin, R. A., Brown, E., Armstrong, A. J., Akerley, W., Benson, A. B., Burstein, H. J., Ettinger, D. S., Febbo, P. G., Fury, M. G., Hudes, G. R., et al. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.2005 · Cited by 49
Vascular Endothelial Growth Factor-Related Pathways in Hemato-Lymphoid Malignancies
Medinger, M., Fischer, N., & Tzankov, A. (2010) · Journal of Oncology · doi:10.1155/2010/729725 · Cited by 52
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer
Dasari, A. N., Gore, L., Messersmith, W. A., Diab, S., Jimeno, A., Weekes, C. D., Lewis, K. D., Drabkin, H. A., Flaig, T. W., & Camidge, D. R. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9812-z · Cited by 47
Hereditary and familial kidney cancer
Coleman, J., & Russo, P. (2009) · Current Opinion in Urology · doi:10.1097/mou.0b013e32832f0d40 · Cited by 46
Combination targeted therapy in advanced renal cell carcinoma
Sosman, J. A., & Puzanov, I. J. (2009) · Cancer · doi:10.1002/cncr.24234 · Cited by 46
Vitamin D3 triggers antitumor activity through targeting hedgehog signaling in human renal cell carcinoma
Dormoy, V., Béraud, C., Lindner, V., Coquard, C., Barthelmebs, M., Brasse, D., Didier Jacqmin, D., Lang, H., & Massfelder, T. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs255 · Cited by 46

Authors: Kaelin, W. G.
Affiliations: Brigham and Women's Hospital (US)
Corresponding author: Kaelin, William G.
ORCID: Kaelin, William G.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2007-01-15
Volume: 13
Issue: 2
Pages: 680s-684s
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-06-1865
OpenAlex: W2131473358
Semantic Scholar: b1ecaaf13be1baca02f75edb325c7d80e991f9a6
Cited by: 336
References: 80
Citations by year: 2026: 13 · 2025: 13 · 2024: 6 · 2023: 9 · 2022: 11 · 2021: 11 · 2020: 9 · 2019: 9 · 2018: 14 · 2017: 13 · 2016: 14 · 2015: 14 · 2014: 18 · 2013: 18 · 2012: 28
FWCI: 5.33
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords: von Hippel-Lindau protein, VHL tumor suppressor, clear cell renal cell carcinoma, hypoxia-inducible factor, HIF-2α, HIF-1α, ubiquitin ligase, vascular endothelial growth factor, platelet-derived growth factor B, transforming growth factor-alpha, VEGF inhibitors, von Hippel-Lindau disease
MeSH terms: Carcinoma, Renal Cell, Genotype, Humans, Kidney Neoplasms, Mutation, RNA, Messenger, Transcription Factors, Signal Transduction, Gene Expression Regulation, Neoplastic, Dimerization, Vascular Endothelial Growth Factor A, Von Hippel-Lindau Tumor Suppressor Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks